Kinetic parameters for reversal of the multidrug pump as measured for drug accumulation and cell killing

Cancer Chemotherapy and Pharmacology

Volumn 38, Issue 2, 1996, Pages 181-190

  Lan, Lu Bin ^a   Ayesh, Suhail ^a   Lyubimov, Elena ^a   Pashinsky, Irina ^a   Stein, Wilfred D ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

cell killing; drug accumulation; kinetics; multidrug resistance; reversal

Indexed keywords

AMIODARONE; AMITRIPTYLINE; CHLORPROMAZINE; CYCLOSPORIN; DAUNORUBICIN; DILTIAZEM; DIPYRIDAMOLE; FLUPHENAZINE; MEFLOQUINE; PROGESTERONE; PROMETHAZINE; PROPAFENONE; PROPRANOLOL; QUINIDINE; RESERPINE; SPIRONOLACTONE; TAMOXIFEN; TERFENADINE; TRIFLUPROMAZINE; VERAPAMIL; VINBLASTINE;

ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CYTOTOXICITY; LEUKEMIA P 388; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL SURVIVAL; CYCLOSPORINE; CYTOTOXINS; DAUNORUBICIN; DRUG RESISTANCE, MULTIPLE; HUMANS; PROPAFENONE; TRIFLUOPERAZINE; VINBLASTINE;

EID: 0029972620     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050468     Document Type: Article

References (42)

1. Endicott JA, Ling V (1989) The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58 : 137-171
2. Gottesman MM, Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62 : 385-427
3. Dano K (1973) Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim Biophys Acta 323 : 466-483
4. Lehnert M (1993) Reversal of P-glycoprotein-associated multidrug resistance: the challenge continues. Eur J Cancer 29 : 636-638
5. Sikic BI (1993) Modulation of Multidrug Resistance -at the threshold. J Clin Oncol 11 : 1629-1635
6. Lum BL, Fisher GA, Brophy NA, Yahanda AM, Adler KM, Kaubisch S, Halsey J, Sikic BI (1993) Clinic trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. Cancer 72: 3502-3514
7. Sarkadi B, Price EM, Boucher RC, Germann UA, Scarborough GA (1992) Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J Biol Chem 267 : 4854-4858
8. Al-Shawi MK, Senior AE (1993) Characterization of the adenosine triphosphatase activity of Chinese hamster P-glycoprotein. J Biol Chem 268 : 4197-4206
9. Ambudkar SH, Lelong IH, Zhang J, Cardarelli CO, Gottesman MM, Pastan I (1992) Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulatable ATP hydrolysis. Proc Natl Acad Sci USA 89 : 8472-8476
10. Shapiro AB, Ling V (1994) ATPase activity of purified and reconstituted P-glycoprotein from Chinese hamster ovary cells. J Biol Chem 269: 3745-3754
11. Reynolds JEF (1993) Martindale -the extra pharmacopeia. Pharmaceutical Press, London
12. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE (1991) P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 9: 17-24
13. Wishart GC, Plumb JA, Morrison JG, Hamilton TG, Kaye SB (1992) Adequate tumour quinidine levels for multidrug resistance modulation can be achieved in vivo. Eur J Cancer 28 : 28-31
14. List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher B, Baier M, Dalton W (1993) Phase-I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 11 : 1652-1660
15. Sridhar KS, Krishan A, Samy TSA, Sauerteig A, Wellham LL, McPhee G, Duncan RC, Anac SY, Ardalan B, Benedetto PW (1993) Prochlorperazine as a doxorubicin-efflux blocker: phase I clinical and pharmacokinetics studies. Cancer Chemother Pharmacol 31 : 423-430
16. Sridhar KS, Krishan A, Samy TSA, Duncan RC, Sauerteig A, McPhee GV, Auguste ME, Benedetto PW (1994) Phase I and pharmacokinetics studies of prochlorperazine 2-h i.v. infusion as a doxorubicin-efflux blocker. Cancer Chemother Pharmacol 34: 377-384
17. Hyafil F, Vergely C, Du Vignaud P, Grand Perret T (1993) In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 53 : 4595-4602
18. Kessel D, Wilberding C (1984) Mode of action of calcium antagonists which alter anthracycline resistance. Biochem Pharmacol 337: 1157-1160
19. Ganapathi R, Grabowski D (1988) Differential effect of the calmodulin inhibitor trifluoroperazine in modulating cellular accumulation, retention and cytotoxicity of doxorubicin-resistant L1210. Biochem Pharmacol 37 : 185-193
20. Loo TW, Clarke DM (1994) Reconstitution of drug-stimulated ATPase activity following co-expression of each half of human P-glycoprotein as separate polypeptides. J Biol Chem 269: 7750-7755
21. Schuurhuis GJ, Broxterman HJ, Cervantes A, van Heijningen TH, de Lange JH, Baak JP, Pinedo HM, Lankelma J (1989) Quantitative determination of factors contributing to doxorubicin resistance in multidrug-resistant cells. J Natl Cancer Inst 81 : 1887-1892
22. Schuurhuis GJ, van Heijningen TH, Cervantes A, Pinedo HM, de Lange JH, Keizer HG, Broxterman HJ, Baak JP, Lankelma J (1993) Changes in subcellular doxorubicin distribution and cellular accumulation alone can largely account for doxorubicin resistance in SW-1573 lung cancer and MCF-7 breast cancer multidrug resistant tumour cells. Br J Cancer 68 : 898-908
23. Pereira E, Garnier Suillerot A (1994) Correlation between the short-term measurements of drug accumulation in living cells and the long-term growth inhibition. Biochem Pharmacol 47: 1851-1857
24. Ramu A, Pollard HB, Rosario LM (1989) Doxorubicin resistance in P388 leukemia -evidence for reduced drug influx. Int J Cancer 44: 539-547
25. Larsson R, Kristensen J, Sandberg C, Nygren P (1992) Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer 50: 177-185
26. Willingham MC, Cornwell MM, Cardarelli CO, Gottesman MM, Pastan I (1986) Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and -sensitive KB cells: effects of verapamil and other drugs. Cane Res 46: 5941-5946
27. Latini R, Tognoni G, Kates RE (1984) Clinical pharmacokinetics of amiodarone. Clin Pharmacokinet 9: 136-156
28. Hutt V, Theodor R, Pabst G, Dilger C, Mosberg H, Fischer W, Jaeger H (1991) Plasma and urine kinetics of amitriptyline oxide and its metabolites. Comparison of intravenous infusion and oral administration in volunteers (in German). Arzneimittelforschung 41 : 367-372
29. Dahl SG (1986) Plasma level monitoring of antipsychotic drugs. Clinical utility. Clin Pharmacokinet 11 : 36-61
30. Samuels BL, Mick R, Vogelzang NJ, Williams SF, Schilsky RL, Safa AR, O'Brien SM, Ratain MJ (1993) Modulation of vinblastine resistance with cyclosporine: a phase I study. Clin Pharmacol Ther 54: 421-429
31. Wiesfeld AC, Remme WJ, Look MP, Kruijssen DA, van Hoogenhuyze DC (1992) Acute hemodynamic and electrophysiologic effects and safety of high-dose intravenous diltiazem in patients receiving metoprolol. Am J Cardiol 70: 997-1003
32. Dresse A, Chevolet C, Delapierre D, Masset H, Weisenberger H, Bozler G, Heinzel G (1982) Pharmacokinetics of oral dipyridamole (Persantine) and its effect on platelet adenosine uptake in man. Eur J Clin Pharmacol 23: 229-234
33. Midha KK, Marder SR, Jaworski TJ, McKay G, Hubbard JW, Hawes EM, Van Putten T, Wirshing WC, Aravagiri M (1993) Clinical perspectives of some neuroleptics through development and application of their assays. Ther Drug Monit 15: 179-189
34. Karbwang J, White NJ (1990) Clinical pharmacokinetics of mefloquine. Clin Pharmacokinet 19: 264-279
35. Christen RD, McClay EF, Plaxe SC, Yen SS, Kim S, Kirmani S, Wilgus LL, Heath DD, Shalinsky DR, Freddo JL, et al (1993) Phase I/pharmacokinetic study of high-dose progesterone and doxorubicin. J Clin Oncol 11 : 2417-2426
36. Patel RB, Welling NJ (1982) High-pressure liquid chromatographic determination of promethazine plasma levels in the dog after oral, intramuscular, and intravenous dosage. J Pharm Sci 71 : 529-532
37. Pritchett EL, Smith WM, Kirsten EB (1988) Pharmacokinetic and pharmacodynamic interactions of propafenone and cimetidine. J Clin Pharmacol 28 : 619-624
38. Vaklivieso A, Calvo R, Suarez E, Gonzalez JP (1993) Propranolol absorption in peptic ulcer disease. Scand J Gastroenterol 28: 643-646
39. Gardiner P, Schrode K, Quinlan D, Martin BK, Boreham DR, Rogers MS, Stubbs K, Smith M, Karim A (1989) Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. J Clin Pharmacol 29: 342-347
40. Trump DL, Smith DC, Ellis PG, Rogers MP, Schold SC, Winer EP, Panella TJ, Jordan VC, Fine RL (1992) High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. J Natl Cancer Inst 84: 1811-1816
41. Shall L, Newcombe RG, Lush M, Marks R (1991) Dose-response relationship between objective measures of histamine-induced weals and dose of terfenadine. Acta Derm Venereol Stockh 71 : 199-204
42. Miller RL, Bukowski RM, Budd GT, Purvis J, Weick JK, Shepard K, Midha KK, Ganapathi R (1988) Clinical modulation of doxorubicin resistance by the calmodulin-inhibitor, trifluoperazme: a phase I/II trial. J Clin Oncol 6: 880-888